The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 4 of the 31 sources its claims cite were checked for support.
Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient.
Open accessAbstract
We report the 1-year results from one patient as the preliminary analysis of a first-in-human phase I clinical trial (ChiCTR2300072200) assessing the feasibility of autologous transplantation of chemically induced pluripotent stem-cell-derived islets (CiPSC islets) beneath the abdominal anterior rectus sheath for type 1 diabetes treatment. The patient achieved sustained insulin independence starting 75 days post-transplantation. The patient's time-in-target glycemic range increased from a baseline value of 43.18% to 96.21% by month 4 post-transplantation, accompanied by a decrease in glycated hemoglobin, an indicator of long-term systemic glucose levels at a non-diabetic level. Thereafter, the patient presented a state of stable glycemic control, with time-in-target glycemic range at >98% and glycated hemoglobin at around 5%. At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities. Promising results from this patient suggest that further clinical studies assessing CiPSC-islet transplantation in type 1 diabetes are warranted.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a first-in-human phase I trial (ChiCTR2300072200), a 25-year-old woman with 11-year type 1 diabetes received an autologous transplant of chemically induced pluripotent stem-cell-derived islets (CiPSC islets) beneath the abdominal anterior rectus sheath and achieved sustained insulin independence from day 75 post-transplantation. At 1 year, all study endpoints were met with no transplant-related abnormalities detected.
Key findings
- The patient achieved complete insulin independence on day 75 and remained insulin-independent through 1 year of follow-up; daily exogenous insulin had been 54 ± 0.9 units/day at baseline.
- Time-in-target glycemic range rose from a baseline of 43.18% to 87.18% at month 2 and 96.21% at month 4, and was >98% for 8 months by the 1-year endpoint; HbA1c fell from 7.57% at baseline to 6.50% at day 75 and 5.37% at day 120, remaining in the non-diabetic range (<5.7%) thereafter.
- Graft function: fasting C-peptide was undetectable at baseline, rose to 59.6–102.6 pmol/L by week 2, and plateaued at 407.1–721.6 pmol/L after insulin independence; BETA-2 score increased from 0.13 at baseline to 21.42 at day 75 and 41.83 at day 365. OGTT peak C-peptide was 1,847.0, 1,439.9, and 2,472.6 pmol/L at days 180, 270, and 365 (3.5-, 2.8-, and 3.4-fold over fasting).
- Safety: no treatment-emergent serious adverse events; treatment-emergent AEs were limited to the peri-transplantation period (puncture-site pain, nausea/vomiting from general anesthesia); no severe hypoglycemic events during follow-up; MRI (T2W-FS and T1W-FS) and tumor markers (β-HCG, AFP, CEA, CA125, CA15-3, CA19-9) showed no evidence of teratoma over 1 year.
Methods
- First patient of an ongoing first-in-human phase I trial (TJFCH-iPS-001; ChiCTR2300072200) evaluating safety, tolerability, and efficacy of autologous CiPSC islets in type 1 diabetes; primary endpoints were HbA1c <7.0% or a ≥1% decrease from baseline at 90–365 days, absence of severe hypoglycemic events, and safety/tolerability; secondary endpoints included insulin independence and stimulated C-peptide ≥0.3 ng/mL.
- Autologous CiPSCs were generated from the patient's adipose-derived mesenchymal stromal cells by a four-step small-molecule chemical reprogramming protocol (clone CiPSC-#8 selected from 23 colonies), then differentiated via a six-stage protocol into islet-like cells; release testing included dd-PCR for residual PSCs, WGS/WES, viability (98%), CHGA positivity (94.5%), and a glucose stimulation index of 1.37.
- 1,488,283 IEQ (19,843 IEQ/kg) were injected under ultrasound guidance into the abdominal anterior rectus sheath on June 25, 2023, across 7 injections; the patient continued existing immunosuppression (tacrolimus, mycophenolate mofetil, methylprednisolone) with basiliximab and etanercept induction. Outcomes were tracked by continuous glucose monitoring, HbA1c, C-peptide, OGTT, BETA-2 score, ultrasound/MRI, tumor markers, and autoantibodies.
Limitations
- Stated by the paper: safety and efficacy beyond 1 year and in more patients remain to be evaluated; the trial includes three patients total, and data from the second and third patients were not yet mature for reporting, so a larger cohort is warranted.
- Stated by the paper: the patient's pre-existing immunosuppression for a transplanted liver precluded evaluation of the recipient's immune response to the autologous graft, limiting insight into potential autoimmune response.
- Evident from the text: this is a single-patient report, so no control group or between-patient comparison is possible, and the concurrent immunosuppressive regimen (including basiliximab and etanercept induction) cannot be separated from the graft's contribution to the observed outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 31 cited sources checked · 4 supported · 0 flagged
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Recently, we successfully reprogrammed human somatic cells to chemically induced PSCs (CiPSCs).”
What the sources say
- Not checked — no full text of the sourcecites [4] 4. Guan, J. ∙ Wang, G. ∙ Wang, J. ... Chemical reprogramming of human somatic cells to pluripotent stem cells Nature. 2022; 605:325-331 Crossref Scopus (178) PubMed Google Scholar source
- Supportedcites [5] 5. Liuyang, S. ∙ Wang, G. ∙ Wang, Y. ... Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming Cell Stem Cell. 2023; 30:450-459.e9 Full Text Full Text (PDF) Scopus (44) PubMed Google Scholar source
The Results report generating hCiPSCs from human somatic cells obtained from all 17 tested donors. The Results also describe tests confirming that the resulting cells meet the criteria for pluripotent stem cells. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thereafter, the patient presented a state of stable glycemic control, with time-in-target glycemic range at >98% and glycated hemoglobin at around 5%.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among them, 50 mice transplanted with the patient’s CiPSC-islets underwent histopathological analysis of major organs (heart, liver, spleen, kidney, lung, and brain) at the end of the observation period (Figure S2D), showing absence of graft-related malignancy even in high-dose transplantation experiments of up to 1 × 107 per mouse (Table S2).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Autologous CiPSCs were induced from adipose-derived mesenchymal stromal cells (ADSCs) isolated from the patient’s adipose tissue by chemical reprogramming as described previously.”
What the sources say
- Not checked — no full text of the sourcecites [4] 4. Guan, J. ∙ Wang, G. ∙ Wang, J. ... Chemical reprogramming of human somatic cells to pluripotent stem cells Nature. 2022; 605:325-331 Crossref Scopus (178) PubMed Google Scholar source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All safety and efficacy clinical endpoints were met at 1-year follow-up of the patient”
- Also stated in: § 1 Send email to zhongyangshen@vip.sina.com … Show more Show less · plain
“At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § 1 Send email to zhongyangshen@vip.sina.com … Show more Show less · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CiPSC-islet preparation met release criteria for transplantation, presenting uniform spheroids between 50–250 μm and scarlet dithizone staining (Figures S3A and S3B), a high viability of 98% (Figure S3C; Table S1, part 3), and a Chromogranin A (CHGA)-positive proportion of 94.5% of total cells (Figures S3D and S3E), of which 56.4% were C-peptide and NKX6.1-positive cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patient CiPSC-islets presented islet-sized aggregates containing approximately 60% β cells, 10% α-like cells, and 10% δ-like cells on average (Figures S1A–S1C).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prior to enrollment, the patient’s plasma C-peptide levels were below the limit of detection (6.6 pmol/L) under both fasting and glucose-challenged conditions.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within 2 weeks after transplantation, the patient’s daily exogenous insulin dose requirement began to reduce from baseline of 54 ± 0.9 units/day (Figure 2A).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
- Probably not a substantial claim. 51
- It may state two separate claims as one. 54
- The quote only partly states this claim. 2
Every source the paper cites for this claim was checked and supports it.
In the paper
“the generation of CiPSCs from somatic cells employs abiotic, small-molecule chemicals as reprogramming factors that are easily manufactured and standardized, non-genome integrating, scalable, and fine-tunable.”
What the sources say
- Supportedcites [6] 6. Wang, J. ∙ Sun, S. ∙ Deng, H. Chemical reprogramming for cell fate manipulation: Methods, applications, and perspectives Cell Stem Cell. 2023; 30:1130-1147 Full Text Full Text (PDF) Scopus (17) PubMed Google Scholar source
The Introduction (passage 6; page not provided) describes small-molecule reprogramming factors as abiotic, easily manufactured and standardized, and non-integrative to the genome. It also calls chemical reprogramming suitable for scalable stem-cell generation and describes the process as controllable and tunable (passage 4). (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Different from conventional iPSCs, which are generated from somatic cells by genetic overexpression of transcription factors, the generation of CiPSCs from somatic cells employs abiotic, small-molecule chemicals as reprogramming factors”
What the sources say
- Supportedcites [6] 6. Wang, J. ∙ Sun, S. ∙ Deng, H. Chemical reprogramming for cell fate manipulation: Methods, applications, and perspectives Cell Stem Cell. 2023; 30:1130-1147 Full Text Full Text (PDF) Scopus (17) PubMed Google Scholar source
The Introduction describes conventional iPSC generation through forced expression of defined genes in somatic cells and contrasts TF-induced reprogramming with chemical reprogramming. It explicitly calls small molecules abiotic reprogramming factors and describes CiPSCs produced through chemical reprogramming. No page numbers are available in our copy. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The small molecules used in the chemical reprogramming approach offer ease of manufacture and standardization and are highly controllable, scalable, and cost-effective, which are important for standardized manufacturing of therapeutic cells.6”
What the sources say
- Supportedcites [6] 6. Wang, J. ∙ Sun, S. ∙ Deng, H. Chemical reprogramming for cell fate manipulation: Methods, applications, and perspectives Cell Stem Cell. 2023; 30:1130-1147 Full Text Full Text (PDF) Scopus (17) PubMed Google Scholar source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CiPSC-islets were found to be glucose-responsive in vitro, with a glucose stimulation index of 1.37 (Table S1, part 3).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the 1-year endpoint, the patient’s TIR had been >98% for 8 months, a substantial improvement in comparison with the baseline TIR of 43.18% (Figure 2C).”
- Also stated in: § Discussion · plain
“ultimately achieving over 98% blood glucose TIR without exogenous insulin use”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The transplanted mice also showed restoration of glucose tolerance and glucose-responsive C-peptide secretion (Figures S2G and S2H).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pancreas graft was removed after a year due to severe thrombotic complications”
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Her HbA1c level during the 2 years before enrollment was 7.40%–8.00%, higher than the American Diabetes Association (ADA)’s recommended target for T1D management (<7.0%).”
What the sources say
- Not matchedcites [29] 29. American Diabetes Association Professional, Practice Committee
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and a Chromogranin A (CHGA)-positive proportion of 94.5% of total cells (Figures S3D and S3E), of which 56.4% were C-peptide and NKX6.1-positive cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The CiPSC-islet preparation also contained 13.4% glucagon-positive cells and 15.9% somatostatin-positive cells, as determined by flow cytometry and immunofluorescence staining (Figures S3D–S3J).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These transplantation experiments showed good survival of patient CiPSC-islets and an absence of teratoma formation or graft overgrowth (Figures S2A and S2B), including mice observed for an extended period of up to 58 weeks;”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A 25-year-old woman was diagnosed with T1D for 11 years (as of time of transplantation in 2023).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Her medical history included two liver transplantations due to cryptogenic cirrhosis in 2014 and 2016, respectively, and a whole pancreas transplantation in 2017 due to unstable glycemic control.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continuous glucose monitoring (CGM) measurements during the three months before transplantation showed severe glucose variability and endangerment by hypoglycemia”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prior to the clinical study, the patient CiPSC-islets were assessed in 244 immunodeficient mice in transplantation experiments, with no tumorigenesis observed in all transplanted mice (Table S2).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After insulin independence, the fasting C-peptide reached a plateau and fluctuated within a range of 407.1 to 721.6 pmol/L.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Her weight was 75 kg, and her body mass index was 27.3 kg/m2.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Based on assessments of panel reactive antibodies (PRAs), the patient was found to be PRA-positive for HLA-I and HLA-II antigens”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient was under regular immunosuppression for liver transplant maintenance.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite receiving intensive insulin treatment at a daily dose of 54 ± 0.9 units (mean ± SD) under the supervision of an endocrinologist, the patient was still not able to achieve target glycemic control.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After CiPSC-islet transplantation, the patient’s fasting serum C-peptide level, which was undetectable at baseline, increased promptly and reached levels ranging 59.6–102.6 pmol/L by the second week after transplantation (Figure 3A).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This was consistent with single-cell RNA sequencing (scRNA-seq) analysis of the patient CiPSC-islets, which also showed ∼13% endocrine progenitor cells and ∼8% enterochromaffin-like cells (Figures S1D–S1F)”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“accompanied by a decrease in glycated hemoglobin, an indicator of long-term systemic glucose levels at a non-diabetic level.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Her fasting glucose fluctuated greatly, with an average value of 210 ± 59 mg/dL (mean ± SD).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A TIR of 87.18% was achieved in the patient at month 2 post-transplantation, which increased to 96.21% at month 4 (Figure 2C).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The data showed that both transcripts were detected in CiPSC-islets at levels lower than the positive control and similar to the negative control, indicating that residual CiPSCs were not detected.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this patient, the transplantation area exhibited signal intensities comparable to the surrounding normal muscle tissue (iso-signal), indicating absence of abnormal fat accumulation (Figures 4I–4P).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Before transplantation, the patient suffered from long-term, hard-to-control diabetes complicated by episodes of severe hypoglycemia.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The blood glucose measurement at the 2 h time point was 155 mg/dL, which is below the diagnostic threshold for diabetes (≥200 mg/dL at 2 h).38”
What the sources say
- Not matchedcites [38]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“OGTT tests on days 180, 270, and 365 visits showed peak C-peptide levels of 1,847.0, 1,439.9, and 2,472.6 pmol/L, respectively, while the fold change in peak C-peptide values relative to the fasting C-peptide values was 3.5, 2.8, and 3.4, respectively (Figure 3D).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The parallel C-peptide levels were 589.2 pmol/L in the fasting state and peaked at 2 h after glucose administration at 1,436.5 pmol/L, showing a 2.4-fold stimulation (Figure 3D).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one. The quote only partly states this claim.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“To improve glycemic control, the patient had previously received a pancreas transplantation in 2017, which had to be removed a year later due to thrombotic complications.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A slight elevation in glutamic acid decarboxylase antibody (GADA) level at one time point was observed.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Karyotype screen of the 23 clones with good morphology and normal cell growth showed abnormal karyotype in one, #11, which was removed from downstream screening.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, good-manufacturing-practice-compliant manufacture of personalized CiPSC-islets for autologous transplantation was conducted, allowing for the first report of clinical transplantation of CiPSC-derived cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Throughout follow-up, the patient was hospitalized one time for an upper respiratory tract infection and was discharged 5 days later.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient’s BETA-2 score increased steadily from a baseline value of 0.13 to 21.42 by the day 75 visit, with the most recent value of 41.83 at day 365 visit (Figure 3E)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin autoantibody (IAA), islet cell antibody (ICA), insulinoma-associated-2 antibodies (IA-2Ab), and zinc transporter 8 antibody (ZnT8) were consistently indicated as negative.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In addition, a whole pancreas transplantation was performed on May 4th, 2017, but the pancreas graft was removed one year later (August 8th, 2018) due to thrombotic complications.”
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“From the day 180 visit, the patient’s glucose tolerance showed further improvement, showing relatively stable performance in OGTTs of subsequent visits thereafter (Figures 3B and 3D).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment-emergent AEs were limited to the peri-transplantation period, which included pain at the puncture area and nausea and vomiting due to general anesthesia.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Before CiPSC-islets transplantation, the patient had undergone two liver transplants on July 8th, 2014 and September 27th, 2016, for liver cryptogenic cirrhosis.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and the one with the highest cell yield was chosen for downstream manufacture (patient CiPSC-#8).”
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the day 120 visit, the meal-responsiveness of C-peptide secretions was further improved, with a fasting level of 407.1 pmol/L and a 2-h postprandial level of 834.1 pmol/L.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this report, we present data from the clinical trial's first participant—a 25-year-old female with an 11-year history of T1D.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Subsequent T2W-FS images taken over the following 365 days after transplantation showed that the signal of the grafts remained consistent and stable in terms of location, shape, size, and magnetic resonance signal intensity, and the left abdominal rectus exhibited no signs of compression, displacement, or deformation, which together showed no indication of abnormal growth (Figures 4D–4H).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The average temperature was -196.2°C, with highest temperature at -190.7°C and lowest temperature at -196.4°C respectively.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“We found that transplantation to an extrahepatic site, underneath the abdominal anterior rectus sheath, led to superior CiPSC-islet survival and maturation, resulting in secretion levels of C-peptide (a marker of endogenous insulin secretion) and stimulation indices approaching those of non-diabetic humans.”
What the sources say
- Not checked — no full text of the sourcecites [21] 21. Liang, Z. ∙ Sun, D. ∙ Lu, S. ... Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets Nat. Metab. 2023; 5:29-40 Crossref Scopus (24) PubMed Google Scholar source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“we established a highly efficient, optimized differentiation protocol for the generation of islet-like cells from CiPSCs (CiPSC-islets), whose transcriptomic identity, composition, and insulin secretory function were comparable to that of native human islets.”
What the sources say
- Not checked yetcites [20] 20. Du, Y. ∙ Liang, Z. ∙ Wang, S. ... Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates Nat. Med. 2022; 28:272-282 Crossref Scopus (85) PubMed Google Scholar
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“with in-process quality control (QC) assessments throughout the manufacturing process.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study was approved by the National Health Commission of the People’s Republic of China and the Medical Ethics Committee at Tianjin First Central Hospital.”
- Also stated in: § Author contributions · plain
“and was approved by the National Health Commission of the People’s Republic of China and the Medical Ethics Committee at Tianjin First Central Hospital”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Also stated in: § Author contributions · plain
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“indicating an increased risk of rejection and graft failure in the case of islet allotransplantation.”
What the sources say
- Not matchedcites [31]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [32]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [33]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient CiPSC-islet manufacturing process was subject to in-process QCs as shown in Table S1, part 2.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Systematic characterization of the selected patient CiPSC line used for downstream manufacture (patient CiPSC-#8) was performed, including trilineage differentiation potential and genomic stability assays.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings supported the viability of CiPSC-islet transplantation underneath the abdominal anterior rectus sheath, which led to relatively rapid restoration of insulin-independent glycemic control in the patient.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In vivo tumorigenicity tests prior to clinical transplantation of patient CiPSC-islets were performed on 50 immunodeficient SCID/Beige mice.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, an extrahepatic site was employed, which was a favorable option for this patient on account of her transplanted liver.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Non-synonymous mutations identified were shown below. The pathogenicity and/or carcinogenicity of these mutations was evaluated by screening of each genomic variants against the COSMIC Census, and their status in COSMIC databases and Clinvar databases, if any, was annotated in the right two columns.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Viability and yield were verified by trypan blue (Invitrogen, T10282) and Countess II Automated Cell Counter (Invitrogen, AMQAX1000).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The BETA-2 score, which used fasting metabolic variables, was derived and validated by Peter Senior, Shareen Forbes, and colleagues from individuals transplanted in the Edmonton Islet Transplantation Program and is widely used in the clinical assessment of graft function after islet transplantation.”
What the sources say
- Not matchedcites [69]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Firstly, safety and efficacy beyond 1 year and in more patients remain to be evaluated.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“while each 1% reduction of HbA1c toward the physiological level has been associated with a 21% reduction in risk of diabetes-related complications and death.52”
What the sources say
- Not matchedcites [52]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Follow-up with these patients is ongoing, as they were sequentially enrolled in accordance with regulatory safety requirements.”
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“and was conducted in accordance to the Clinical Study Protocol (Data S1).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Whole-genome sequencing data and whole-exome sequencing data (WGS and WES) were generated for the patient’s ADSCs, CiPSC line, and the patient’s CiPSC-islets.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Flow cytometry was performed in dissociated cells for islet endocrine cell-related markers (NKX6.1, C-peptide, GCG, SST).”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“During this time before transplantation, the items in Quality control and final check of CiPSC-islets preparation before transplantation (as shown in Table S1 Part 3) were tested as a final check.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The current patient provided written informed consent to undergo the procedure.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Secondly, the use of immunosuppressants in this patient precluded the evaluation of immune response of the recipient to the autologous graft.”
- Also stated in: § Discussion · hedged
“but insight into potential autoimmune response was limited.”
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Discussion · hedged
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, due to the limited follow-up period and according to our clinical trial protocol, data from these two patients are not yet matured for reporting.”
Strength:plain· not yet calibratedn = 2Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together, these findings indicate the feasibility of chemically induced autologous PSCs for cell therapy, constituting a viable personalized medicine strategy.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Glucose stimulated insulin secretion (GSIS) assay was conducted to evaluate the Glucose Stimulation Index (GSI) of functional potency.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“In comparison to intraportal transplantation, the abdominal rectus sheath site also encompasses other safety considerations, such as ease of access for transplantation and imaging and site retention of graft.21”
What the sources say
- Not checked — no full text of the sourcecites [21] 21. Liang, Z. ∙ Sun, D. ∙ Lu, S. ... Implantation underneath the abdominal anterior rectus sheath enables effective and functional engraftment of stem-cell-derived islets Nat. Metab. 2023; 5:29-40 Crossref Scopus (24) PubMed Google Scholar source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“For the CiPSC induction, a four step chemical reprogramming protocol without genetic manipulation was applied to patient ADSCs as described previously.4”
What the sources say
- Not checked — no full text of the sourcecites [4] 4. Guan, J. ∙ Wang, G. ∙ Wang, J. ... Chemical reprogramming of human somatic cells to pluripotent stem cells Nature. 2022; 605:325-331 Crossref Scopus (178) PubMed Google Scholar source
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“the viability of CiPSC-islets was tested by fluorescein diacetate (FDA) / propidium iodide (PI) staining.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“CiPSC-islet cell recovery and preparation was conducted at the clinical site under GMP-level conditions.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial is ongoing and includes three patients in total.”
Strength:plain· not yet calibratedn = 3Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Data from another clinical trial (NCT04786262), which transplanted hPSC-derived islets into the hepatic portal vein, were recently announced, the findings of which also indicated positive outcomes post-transplantation.60”
What the sources say
- Not matchedcites [60]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Short tandem repeat (STR), whole genome sequencing (WGS) and whole exome sequencing (WES) tests were conducted on the selected clone #8, which passed all the tests.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together with our preclinical studies, the clinical data in this report support the clinical value of this transplantation strategy, warranting continued exploration.”
Tests✓ Asserted: passes? Checkable: unclear✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The patient CiPSC-#8 cell line was assessed for quality according to the requirements in Table S1 Part 1.”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the Declaration of Helsinki”
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Thorough testing of the final CiPSC-islets was conducted to detect for residues of concern, including residual BSA and cytokines.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“C-peptide measures taken in parallel showed undetectable C-peptide levels (Figure 3D), indicating a complete destruction of β cells and poor glucose tolerance.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, mycoplasma contamination, sterility and endotoxin levels were checked according to protocols in the Chinese pharmacopoeia (2020 version).”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The reagents used in the entire manufacturing process was subject to reagent controls, including checking documentation of certificates of analysis (COA) of every reagent.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Prior to the start of patient recruitment, the trial was registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2300072200).”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We performed droplet digital PCR (dd-PCR) to verify biosafety of patient CiPSCs-islets.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together, these results indicated good graft function of the transplanted CiPSC-islets and recovery of endogenous, glucose-responsive insulin secretion in the patient.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All of the mouse experiments performed were approved by the Institutional Animal Care and Use Committee of Peking University.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The extraperitoneal transplant site has minimal invasiveness of injection and ease of imaging.
“Other important advantages of this self-contained extraperitoneal transplant site include minimal invasiveness of injection at the site and ease of imaging.”
The paper relies on this without support.
The clinical improvements observed after transplantation are attributable to the transplanted CiPSC-islets rather than to other factors such as the immunosuppressive regimen, residual endogenous insulin secretion, or the natural history of the patient’s diabetes.
“After CiPSC-islet transplantation, the patient achieved insulin independence within 3 months post-transplantation, ultimately achieving over 98% blood glucose TIR without exogenous insulin use.”
The paper relies on this without support.
The absence of tumorigenicity observed in mice and nonhuman primates predicts the absence of tumorigenicity in the human patient.
“Prior to the clinical study, the patient CiPSC-islets were assessed in 244 immunodeficient mice in transplantation experiments, with no tumorigenesis observed in all transplanted mice (Table S2).”
The paper relies on this without support.
The patient’s immunosuppressive maintenance regimen did not confound the glycemic or graft-function outcomes attributed to the CiPSC-islet transplant.
“the immunosuppressive maintenance regimen included tacrolimus, mycophenolate mofetil, and methylprednisolone tablets, which were continued after CiPSC transplantation”
The paper relies on this without support.
The abdominal anterior rectus sheath site is safe and effective for stem-cell-derived islet transplantation in humans based on preclinical studies.
“The positive metabolic data seen in this clinical study are consistent with that seen in our preclinical study in nonhuman primates, in which we sought to identify an optimal transplant site for CiPSC-islets.21”
The paper relies on this without support.
Type 1 diabetes is an autoimmune disease.
“Because T1D is an autoimmune disease”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These studies indicate that current technology can produce stemcell derived β cells capable of reversing type 1 diabetes (figure 2).”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“In this study, the cells were transplanted into the rectus sheath in the anterior abdominal wall (table 3).72”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“These induced pluripotent stem cells were generated by chemical reprogramming of the cells using small molecules to dedifferentiate the cells rather than genetic methods.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“Another landmark event in type 1 diabetes treatment was the reversal of diabetes with β cells derived from autologous induced pluripotent stem cells in a recipient with previous liver transplantation and therefore on immunosuppression.72”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“Although stemcell therapy has shown remarkable results in a few people, 71,72 its promise as a therapy for broad application is dependent on the safe engineering of cells that avoid both alloimmunity and autoimmunity, and on production methods that meet the global demand for cellbased therapy at affordable costs.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Cryopreserved cells per vial differ between preparation and thawing
MajorThe stated cryopreservation concentration and 4 mL aliquot give 1.2 × 10^8 cells per vial, but the thawing procedure says each vial contained 1.8 × 10^8 cells.
“On day 0, 40 cryopreserved vials of CiPSC-islet cells (1.8 × 108 cells per vial) were thawed in a 37 °C water bath.”
“cells were suspended at 3 × 107 cells/mL in cryopreservation medium (5% dimethylsulfoxide (DMSO) (Sigma-Aldrich, D2650), 60% stage 6 medium, 35% FBS and 10 μM Y27632). Then, a 4 mL cell suspension was aliquoted into 5 mL vials.”
Claim of no added immunosuppression conflicts with induction therapy
MinorThe paper says the transplantation did not add to the patient's immunosuppression burden, but it also reports giving basiliximab as induction therapy in addition to her existing maintenance regimen.
“this allowed the assessment of therapeutic capacity of CiPSC-islets without adding to the patient’s immunosuppression burden”
“For CiPSC-islets transplantation, Basiliximab (20 mg) was used for induction therapy on day 0 and day 4.”
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Dictionary learning for integrative, multimodal and scalable single-cell analysis
Hao, Y., Stuart, T., Kowalski, M. H., Choudhary, S., Hoffman, P., Hartman, A., Srivastava, A., Molla, G., Madad, S., Fernandez-Granda, C., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01767-y · Cited by 5,631
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells
D’Amour, K. A., Bang, A. G., Eliazer, S., Kelly, O., Agulnick, A. D., Smart, N. G., Moorman, M. A., KROON, E. J., Carpenter, M. K., & Baetge, E. E. (2006) · Nature Biotechnology · doi:10.1038/nbt1259 · Cited by 1,913
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–281 of 281
Darwish, R., Alcibahy, Y., Nandakumar, M., Butler, A. E., & Moin, A. S. M. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04739-y
“Results showed that she was insulin-independent 75 days post-transplantation and remained that way for the entire follow-up period of 1 year documented in the report [145].”
Deng, Z., Li, M., Wang, Y., Li, W., Gong, Z., Liao, P., Luo, S., Liu, M., & Deng, X. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.12.057
“Tissue engineering is a promising approach for tackling degenerative diseases and injuries such as type 1 diabetes [1], Alzheimer's disease [2], and bone defects [3], which have achieved remarkable improvements in the physical health of patients.”
Zheng, C., Lu, S., Qiang, D., Xu, J., & Xu, Y. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70120
The dawn of regeneration: From scientific fantasy to clinical reality
Li, L., Xing, Y., Zhang, Q., Wang, Y., & Zeng, W. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40423-8.00009-9
Cao, L., Han, R., Xiong, H., Li, Q., Tao, S., Wu, X., & Liu, D. (2026) · Advanced Science · doi:10.1002/advs.202518597 · Cited by 1
“Mesenchymal stem cells (MSCs) have demonstrated significant potential for clinical application in the treatment of diseases and tissue damage, primarily through their ability to govern the repair and regeneration of damaged tissues [ 4–6 ].”
Could gene therapy delivered to the liver cure type 1 diabetes?
Nolan, C. J. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.014
A Paradigm Shift in Islet Transplantation Driven by Stem Cell Technology and Gene Modification
Rickert, C. G., & Stock, P. G. (2026) · Transplantation · doi:10.1097/tp.0000000000005654
Generation of Functional β Cells from Pluripotent Stem Cells: Advances and Applications
Khashim, Z., & Peterson, Q. P. (2025) · Biochemistry · doi:10.5772/intechopen.1011979
Liu, J., & Grapin‐Botton, A. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.01.004
Chen, G., Ma, X., Jiang, L., Zhou, Z., Li, Q., Deng, Q., Li, Y., He, Y., Wang, Y., Wang, X., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116990
Self-citationHuang, X., chen, Q., & LU, H. (2026) · Research Square · doi:10.21203/rs.3.rs-8461181/v1
Tu, H., Hosaka, A., Hichiwa, G., Wang, Y., Kazuki, K., Tabata, T., Osaki, M., Nakayama, Y., Kanazawa, I., Honma, K., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04977-8
“Emerging technologies such as chemically induced pluripotent stem cells (CiPSCs) are advancing to clinical trials [44], demonstrating the real-world potential of reprogramming-based therapies.”
DiLisio, J. E., Beard, K. S., Neef, T., Miller, S. D., Wenzlau, J. M., Nakayama, M., D’Antonio, M. A., Jamison, B. L., Nicholson, K., Baker, R. L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70878-2 · Cited by 1
Stem Cells for the Therapy of Neurodegeneration
Полтавцева, Р. А., Svirshchevskaya, E. V., Tchikov, V. M., Bobkova, N. V., & Sukhikh, G. T. (2026) · Cell and Tissue Biology · doi:10.1134/s1990519x2603003x
Emerging therapeutic strategies for type 1 diabetes
Tselousova, J., Lugovaya, L. A., Kuchin, D. M., Vasilchikova, E. A., V., Е. P., Kashina, A. V., & Загайнов, В. Е. (2026) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2026-1-212-226
Xu, J., Shen, X., Gu, Y., Lewis, D. F., Zoorob, D. G., & Wang, Y. (2026) · PROTEOMICS · doi:10.1002/pmic.70120
“Early-phase clinical trials have demonstrated the feasibility of this approach, with preliminary data indicating that stem cell-derived Ins-PCs are capable of functional insulin secretion in vivo [ 34– 37 ].”
Sun, H., Qi, X., Chen, S., Huang, Y., Zheng, X., Li, Y., Li, N., Shi, J., Xu, D., Hao, X., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115659
Autologous airway basal cell transplantation for destroyed lung repair
Zheng, Q., Bai, Y. S., Gu, X., Li, Z., Guo, Z., Liu, Q., Xu, J. F., xi, Y., Huang, C., & Ren, T. (2026) · Translational research · doi:10.1016/j.trsl.2026.04.002
Development of Nanoflare Nanosensors for Monitoring Cellular Insulin mRNA in Beta Cells and Islets
Hu, Y., Zhang, Q., Tianli, H. U., Liu, J., Fu, H., Zhao, X., Yang, Z., & Xu, C. (2026) · Advanced Materials Technologies · doi:10.1002/admt.202501702
“Notably, recent advances have achieved long-term insulin independence in diabetic patients [ 9 ], supporting the clinical potential of stem cell-based β -cell replacement.”
Five Advances in Benign Pancreatic Surgery in the Last 50 Years
Dreyer, S. B., & Parks, R. W. (2026) · World Journal of Surgery · doi:10.1002/wjs.70369
Tromper le système immunitaire pour faire décoller la thérapie cellulaire du diabète
Benhamou, P. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.04.003
Diané, A., Mu-u-min, R., Al-Shukri, N. A., Nour‐Eldine, W., & Al-Siddiqi, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1795738 · Cited by 1
“The importance of mitochondria for b -cell function is well known (39) and functionally mature stem cell-derived b -cell organoids show great promise as an alternative and renewable source for cell therapy for individuals with T1D (40, 41).”
Zitzmann, F. D., Remmert, C., Rogers, N. K., Schmidt, S., Lickert, H., Jahnke, H.-G., & Meier, M. (2026) · Biosensors & bioelectronics · doi:10.1016/j.bios.2026.118720
La thérapie cellulaire du diabète de type 1
Gauthier, E., & Boos, M. (2026) · médecine/sciences · doi:10.1051/medsci/2026063
Rejuvenating stem cells to reverse aging
Ranwa, S., Yadav, S., Nurboo, S., & Nazir, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33159-6.00019-9
Rao, J. S., Guo, Z., Khashim, Z., Knofczynski, K. R., Tobolt, D. K., Shivakumar, S. B., Rangarajan, P., Herman, A., Abdulla, M., Tran, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.25.720819
Evaluating iPSC-based interventions for diabetes: a systematic review and meta-analysis
Tan, V. M., Anh, K. T. L., Hiền, L. T., Trang, V. T. T., Nguyet, P. M., Linh, D. P., Yen, T. T. H., & Quan, V. D. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02168-2
Heimbach, J. K., Bumgardner, G. L., Sudan, D. L., Pomfret, E. A., & Markmann, J. F. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.03.031
Yuan, L.-Y., Yuan, Q., Guo, D.-W., Tan, H.-L., & Guan, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1821763
Liao, Z., Zhao, C., Wang, L., et al. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01580-5
“Human pluripotent stem cells (hPSCs) possess robust self-renewal capacity, endowing them with broad applicability in regenerative medicine and personalized therapy [1] [2].”
Wang, Y., Nozhat, Z., Duan, T., Chen, S., Ni, Y., Wang, Y., Shen, C., & You, M. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.37
Snowball, J., Salem, V., Wu, M., & Blackman, S. M. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.05.008
Stem cells have potent potential for diabetes treatment
Laforest, B., & Bruin, J. E. (2026) · The Conversation · doi:10.64628/aam.7avhafpxq
What Is the Current State of Stem Cell Therapy in Diabetes?
Bakinowska, E., Biniek, W. J., Kiełbowski, K., Dyrka, K., Szewczyk, K., Ostałowska, H., Leciej, Z., & Pawlik, A. (2026) · Cells · doi:10.3390/cells15100907
“For instance, Wang et al. [22] described the clinical use of chemically induced PSC-derived islets in 25-year-old T1DM patients with a history of two liver transplantations and a complete pancreatic transplantation.”
InfluentialFiancette, R., Huang, J., Stephens, C., Hibbert, J. E., Hewitt, G., Carlein, C., Shilleh, A. H., Clinton, C., Osório, L. A., Tourigny, D. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.726825 · Cited by 1
“Recently published protocols also achieve similar β -cell proportions using modified protocols 18,26,27,61,62 , with some deploying mid-scale bioreactors 18,26,29 .”
He, D.-W., Zhang, F., Zhang, H.-X., Xiao, S.-Y., Bi, X.-Y., Wang, Y.-M., Wang, R.-L., Lu, Y.-X., Yin, H., & Li, T. (2026) · World Journal of Diabetes · doi:10.4239/wjd.119760
Choi, M., Shanto, P. C., Fahad, M. A. A., Bae, S., & Lee, B. H. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.03.001
Bühler, B. D., Taeye, S. D., Kinoshita, K., Terashita, M., Maenaka, A., Lavalla, G., Burdorf, L., Bottino, R., & Cooper, D. K. C. (2026) · Diabetes · doi:10.2337/db25-0769 · Cited by 1
Advances in vascularized organoids
Shen, L., Ma, J. F., Wei, X., Shi, G., & Deng, H. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004136
Self-citationEngineering organoids toward implantable living therapeutics
Shi, Z., Yang, Q., You, X., Wang, H., Wang, H., & Zhao, G. (2026) · hLife · doi:10.1016/j.hlife.2026.06.002
“Mean-while, chemical reprogramming has emerged as a promising approach for maintaining genomic stability and reducing the risks associated with viral vectors and gene editing [113,161].”
Pancreatic organoids and organoid-on-a-chip platforms: from disease modeling to precision therapy
Lin, M., Ma, W., Ma, T., He, Y., Shi, H., Ge, N., Guo, J., Xie, Y., Sun, S., & Yang, F. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08489-0
The regulation of stem cell fate and its application in neural regeneration
He, Y., Chen, X., He, M., & Li, Z. Y. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70137
Yaseen, Z., & Mothilal, M. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11184-8
“Importantly, MSC-derived IPCs approaches have already entered early clinical evaluation, including autologous AD-MSC-derived CiPSC islet transplantation and IPC infusion studies, reflecting growing interest in MSC-based β-cell replacement strategies (Table 1) [74, 75, 76].”
Tolerance meets regenerative medicine: A new route to donor-specific allograft acceptance?
Jull, P., & Issa, F. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.06.001
Guttikonda, S., Machur, J. C., Matha, C. P., Mathew, R. R., & Thotakura, T. (2026) · Cureus · doi:10.7759/cureus.111930
“In 2024, a groundbreaking clinical trial reported the first functional cure of T1D using autologous CiPSC-derived islets [10].”
InfluentialXu, S., Fang, L., Qiu, J., Li, J., Li, Y., & Liu, J. (2026) · The FASEB Journal · doi:10.1096/fj.202602555r
Kawaguchi, Y., Nakayama, M., Kanetaka, K., Higashi, M., Maruya, Y., Kobayashi, S., Matsumura, M., Naka, T., & Eguchi, S. (2026) · Cell Transplantation · doi:10.1177/09636897261466845
Huang, X., chen, Q., & Lü, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1856373
“Various strategies have been proposed, including the use of donor – speci fi c autologous cells (26, 27), physical barriers such as microencapsulation to prevent immune rejection (79), and co – transplantation with immunoregulatory cells (79, 80).”
InfluentialJin, M., Song, S.-J., Liang, J., Li, L.-D., Zhang, K.-J., Shen, W., Kalds, P., Chen, Y.-L., & Wang, X.-L. (2026) · Journal of Integrative Agriculture · doi:10.1016/j.jia.2026.07.008
Self-citationApplications of Stem Cell–Derived Islets and Emerging Experimental Platforms to Understand Diabetes
Mukherjee, N., & Millman, J. R. (2026) · Diabetes · doi:10.2337/db26-0013
“In 2024, Wang et al. (16) transplanted SC-islets derived from T1D patients beneath the abdominal anterior rectus sheath.”
Drummond, R. F., Seif, K. E., & Reece, E. A. (2026) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2026.07.009
Fehri, M. F. E., & Ferdaoussi, M. (2026) · médecine/sciences · doi:10.1051/medsci/2026111
Chen, F. Z., Zhu, Y., Chen, J., & Chen, J. (2026) · Food Reviews International · doi:10.1080/87559129.2026.2695263
Luo, Q., Yang, J., Huang, J., Lin, N., Liu, W., Huang, Z., Wang, H. Y., Yao, J., Xiao, J. N., Zhu, H., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03957-2
“This strategy not only minimizes the risk of allogeneic immune rejection and avoids adverse events associated with systemic immunosuppression, but also enables truly individualized precision therapy [62].”
Self-citationImmuntherapie und Zelltherapie bei Diabetes mellitus Typ 1
Schill, S., Schwenker, L., Reinmüller, F., Achenbach, P., & Ziegler, A. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02167-5
Simaeys, D. V., & Berggren, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02934-8
“…reaction (IBMIR) 9 has motivated continued investigation of extrahepatic sites, including the kidney capsule, omental, subdermal and intramuscular implantation, 11,12 and the recently described anterior rectus sheath, 4 each presenting a distinct vascular and in fl ammatory microenvironment.”
Krupalnik, V., Kawamata, S., Mountford, J. C., Muschler, G. F., Bando, H., Cui, W., Zhang, X., Ludwig, T. E., Munsie, L., Agabalyan, N. A., et al. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102969
Zhou, J., Lin, X., Yan, L., Cha, Z., Li, J., & Xu, H. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2026.06
Green, B. D., & Auci, D. L. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.08.001
The evolution of iPSC-based cell therapy across autologous and allogeneic pathways
Wang, A., Zhang, Y., Deng, H., & Gu, M. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102992
“107 Autologous hCiPSC-derived islet-like cells were transplanted underneath the abdominal anterior rectus sheath.”
InfluentialSelf-citationChen, M., Zuo, N., Wang, Q., Zhao, H., Dai, P., Liang, S., Zhu, W., Zhang, H., Iqbal, M. O., Dong, D., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1931336
“…showed that endogenous autonomous and physiological blood glucose control was restored after transplantation, and they were completely and stably separated from insulin injection therapy 75 days after transplantation, and the effect has been stable for more than 1 year now (Wang et al., 2024a).”
Self-citationPancreatic islets: new discoveries for innovative treatments of diabetes?
Scharfmann, R., & Zaldumbide, A. (2026) · Diabetologia · doi:10.1007/s00125-026-06839-7
“…to better assess the intra-islet communication and better understand the complex crosstalk that precedes immune cell infiltration, but also to prepare the next-generation iPSC-derived islet product for the achievement of precise blood glucose management in individuals with type 1 diabetes [78].”
Wu, F., Wei, X., Zhao, W., He, L., Gao, B., Luo, Y., Zhou, W., Chai, Y., Wang, Y., Wu, B., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c03666
Self-citationLi, H., Long, P., Qin, W., Chen, X., Liao, C., Shi, H., Liu, Y., & Gao, L. (2026) · ACS Materials Letters · doi:10.1021/acsmaterialslett.6c00481
Induced pluripotent stem cells from discovery to translation
Lee, J., Herron, T. J., Studer, L., Mummery, C. L., & Wu, J. C. (2026) · Nature Medicine · doi:10.1038/s41591-026-04584-3 · Cited by 2
Stem cell strategies for cell replacement therapy in endocrine diseases
Mi, C., Xie, C., Tang, J., Gao, Y., Zhang, J., Yang, Y., Tan, G., Zheng, C., & Liu, H. (2026) · Cell Transplantation · doi:10.1177/09636897261486242
Kobaisi, F., Oshima, M., Zhou, Z., Thibaut, D., Kobaisi, A., Brandao, B., Mallone, R., & Scharfmann, R. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117941
Scalable generation of T lymphocytes from human pluripotent stem cells in suspended organoids
Lei, Q., Miao, Y., Zheng, F., Cheng, R., Mo, Y., Lai, W., Zhou, Z., Lv, L., He, Y., Xie, H., et al. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.103076
Self-citationThe comparative cell physiology of stem cell-derived and primary human β cells
Maghera, J., Chu, C. M. J., Schaaf, C., Bruin, J. E., Johnson, J. D., Lynn, F. C., & MacDonald, P. E. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01295-0 · Cited by 1
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06833-z
Hirani, K., Blaschke, C., Olloqui, C., & Mittal, R. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1915502
“Advances in stem cell biology have created new opportunities to generate insulin-producing cells from pluripotent stem cell platforms capable of differentiating into β -like cells that closely resemble native endocrine cells in both structure and glucose-responsive insulin secretion (204, 216–218).”
Bandral, M., Alvarez‐Castanon, J., & Lorberbaum, D. S. (2026) · Current Protocols · doi:10.1002/cpz1.70467
“In fact, several ongoing clinical trials using SC-islets have provided exciting results illustrating the utility of these cells (Agulnick et al., 2015; Pullen, 2022; Wang et al., 2024).”
Cochrane, V. A., Sterr, M., Aniag, M., Jiménez, S., Wang, M. S., Liu, Y., Boos, A., Merl‐Pham, J., Anand, A., Hoang, R. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.29.755533
Self-citationOdorico, J. S., Citro, A., de Koning, E. J. P., Kay, T., Latres, E., Millman, J. R., Nostro, M. C., Piemonti, L., Rickels, M. R., Russ, H. A., et al. (2026) · Transplantation · doi:10.1097/tp.0000000000005783
Chen, L., Hu, X., Zheng, C., Huang, Q., Xu, J., You, X., & Wang, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1981945
“The same site was later used for autologous chemically induced iPSC-derived islets in a fi rst-in-human study (31).”
InfluentialPancreas Transplant Training in the United States: Trends and Implications
Nagaraju, S., Harris, M. K., & Dunn, T. B. (2026) · Current Transplantation Reports · doi:10.1007/s40472-026-00529-4
“Optimistic prelimi-nary reports of cell transplant trials are also emerging [10, 11 ].”
Wang, J., Pélissier, A., Lin, J. S. H., Quintard, C., TAMAKHINA, A., Wang, J., Jiao, J., Werschler, N., An, M., Kozieradzki, I., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.09.011 · Cited by 1
Epigenetics in development, disease, and therapy: from mechanisms to clinical interventions
Ren, Y., Yang, L., Fei, B., Guo, R., Huang, J., Xu, Z., Wang, R., Zhang, P., Cao, D., Chen, P., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3356-1
Self-citationhiPSC-derived new approach methodology (NAM) recapitulates hallmarks of atrial fibrillation
Kozlowski, P., Muthukumarasamy, K. M., Buranello, T. W., Jo, S., Deshmukh, A., da Rocha, A. M., & Oral, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1814075
Leavens, C. M., Chamberlain, C. S., Kapadia, D., Jurrens, N., Estrada, E. J., Talerico, K., Arroyo, M., -, P. D., & Odorico, J. S. (2026) · Regenerative Medicine · doi:10.1080/17460751.2026.2751695
Metadata
- Authors
- Wang, S., Du, Y., Zhang, B., Meng, G., Liu, Z., Liew, S. Y., Liang, R., Zhang, Z., Cai, X., Wu, S., Gao, W., Zhuang, D., Zou, J., Huang, H., Wang, M., Wang, X., Wang, X., Liang, T., Liu, T., Gu, J., Liu, N., Wei, Y., Ding, X., Pu, Y., Zhan, Y., Luo, Y., Sun, P., Xie, S., Yang, J., Weng, Y., Zhou, C., Wang, Z., Wang, S., Deng, H., & Shen, Z.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Nankai University (CN)
- Corresponding author
- Wang, Shusen
- Deng, Hongkui
- Shen, Zhongyang
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2024-10
- Volume
- 187
- Issue
- 22
- Pages
- 6152-6164.e18
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4402843606
- Semantic Scholar
- 53d12206f7b2371dbe9f6cc2db7448dfa741cad5
- Cited by
- 281
- References
- 70
- Citations by year
- 2026: 120 · 2025: 143 · 2024: 17
- FWCI
- 117.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 395 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82070805, 32288102, 82100841, NKTM2023002)
- Tianjin Municipal Human Resources and Social Security Bureau (XB202011)
- Tianjin Municipal Science and Technology Bureau (22JCZXJC00110, 2023C03019)
- National Key Research and Development Program of China (2020YFA0803704)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- type 1 diabetes, islet transplantation, autologous transplantation, anterior rectus sheath, insulin independence, glycemic control, HbA1c
- MeSH terms
- Single-Case Studies as Topic, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Insulin, Islets of Langerhans, Male, Islets of Langerhans Transplantation, Rectus Abdominis, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
